Matching articles for "ipilimumab"
Issue 1705 · June 24, 2024
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)

The FDA has approved tebentafusp-tebn ( Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic…

Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e107-8 doi:10.58347/tml.2024.1705f
The FDA has approved tebentafusp-tebn ( Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.
Issue 1702 · May 13, 2024
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)

The FDA has approved tislelizumab ( Tevimbra – BeiGene), a programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic esophageal squamous cell cancer in adults who…

Med Lett Drugs Ther. 2024 May 13; 66(1702):e85-6 doi:10.58347/tml.2024.1702h
The FDA has approved tislelizumab ( Tevimbra – BeiGene), a programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic esophageal squamous cell cancer in adults who received prior systemic chemotherapy that did not include a programmed death ligand-1 (PD-L1) inhibitor.
Issue 1701 · April 29, 2024
Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)

Lifileucel ( Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma…

Med Lett Drugs Ther. 2024 Apr 29; 66(1701):e77-8 doi:10.58347/tml.2024.1701h
Lifileucel ( Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma previously treated with a programmed death receptor-1 (PD-1) inhibitor, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a mitogen-activated kinase (MEK) inhibitor. It is the first cellular therapy to be approved for use in solid tumors. Accelerated approval of lifileucel was based on objective response rates.
Issue 1668 · January 23, 2023
Opdualag for Metastatic Melanoma (online only)

Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3)…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):e19-20 doi:10.58347/tml.2023.1668g
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old. Relatlimab, which is only available in combination with nivolumab, is the first LAG-3 blocking antibody to become available in the US. Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab (Yervoy) and the PD-1 inhibitors nivolumab and pembrolizumab (Keytruda) , have been available for several years for treatment of melanoma.
Issue 1491 · March 28, 2016
Cobimetinib (Cotellic) for Metastatic Melanoma

The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib ( Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib…

Med Lett Drugs Ther. 2016 Mar 28; 58(1491):43-4
The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib ( Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib (Zelboraf) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Issue 1483 · December 7, 2015
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma

The FDA has approved the combined use of the programmed death receptor-1 (PD-1) blocking antibody nivolumab (Opdivo) and the anti-CLA-4 antibody ipilimumab (Yervoy) for treatment of BRAF V600 wild-type…

Med Lett Drugs Ther. 2015 Dec 7; 57(1483):168
The FDA has approved the combined use of the programmed death receptor-1 (PD-1) blocking antibody nivolumab (Opdivo) and the anti-CLA-4 antibody ipilimumab (Yervoy) for treatment of BRAF V600 wild-type unresectable or metastatic melanoma. This is the first immunotherapy combination to be approved for treatment of any type of cancer.
Issue 1471 · June 22, 2015 Free
Addendum: Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

After our article on nivolumab ( Opdivo – BMS) for treatment of metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) was published in the most recent issue of The Medical Letter…

Med Lett Drugs Ther. 2015 Jun 22; 57(1471):94
After our article on nivolumab ( Opdivo – BMS) for treatment of metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) was published in the most recent issue of The Medical Letter (June 8, 2015), 1 some new data became available supporting the efficacy of the drug in previously untreated melanoma and previously treated nonsquamous NSCLC. MELANOMA – In a double-blind trial, 945 patients with previously untreated, unresectable stage III or IV melanoma were randomized to receive ipilimumab, nivolumab, or combination therapy with ipilimumab and nivolumab. Progression-free survival, a primary endpoint, improved by 43% with nivolumab (median 6.9 months) and by 58% with combination therapy (median 11.5 months), compared to ipilimumab (median 2.9 months). In patients with tumors that expressed the programmed death ligand 1 (PD-L1) on ≥5% of cells, median progression-free survival was similar in the nivolumab and combination groups (both 14.0 months); in those with tumors that expressed PD-L1 on <5% of cells, it was 5.3 months with nivolumab alone and 11.2 months with both drugs. Rates of complete or partial response were 19.0% with ipilimumab, 43.7% with nivolumab, and 57.6% with combination therapy. At least one severe (grade 3-4) drug-related adverse effect occurred in 27.3% of patients receiving ipilimumab, 16.3% of those receiving nivolumab, and 55.0% of those receiving both drugs. 2 NONSQUAMOUS NSCLC – In an open-label trial (available only as an abstract), 582 patients with advanced nonsquamous NSCLC that had progressed during or after treatment with a platinum doublet-based regimen (and, if appropriate, a kinase inhibitor) were randomized to receive nivolumab or docetaxel until disease progression or unacceptable toxicity occurred. Nivolumab significantly improved overall survival, the primary endpoint, by 27% compared to docetaxel (median 12.2 vs 9.4 months). Survival rates in the two groups were similar in patients with tumors expressing PD-L1 on <1% of cells, but in patients with tumors expressing PD-L1 on ≥1%, ≥5%, and ≥10% of cells, nivolumab improved overall survival by 41%, 57%, and 60%, respectively, compared to docetaxel. Patients receiving nivolumab were significantly more likely to have an objective response (19.2% vs 12.4%). Severe (grade 3+) drug-related adverse effects occurred in 10.5% of patients receiving nivolumab and in 53.7% of those receiving docetaxel. 3 Nivolumab (Opdivo) for metastatic melanoma and metastatic NSCLC. Med Lett Drugs Ther 2015; 57:85. J Larkin et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015 May 31 (epub). L Paz-Ares et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (suppl; abstr LBA109). Available at: abstracts.asco.org. Accessed June 11, 2015. Download complete U.S. English article
Issue 1470 · June 8, 2015
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

The FDA has approved nivolumab ( Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with…

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):85-7
The FDA has approved nivolumab ( Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda) , and the first to be approved for treatment of NSCLC.
Issue 1455 · November 10, 2014
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)

The FDA has approved pembrolizumab ( Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following…

Med Lett Drugs Ther. 2014 Nov 10; 56(1455):e114-5
The FDA has approved pembrolizumab ( Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (Yervoy) and, if the patient is BRAF V600 mutation positive, a BRAF inhibitor. It is the fi rst PD-1 inhibitor to be marketed in the US. Nivolumab, another PD-1 inhibitor, is available in Japan. Pembrolizumab was previously known as lambrolizumab.
Issue 1422 · August 5, 2013
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma

The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib ( Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib ( Mekinist –…

Med Lett Drugs Ther. 2013 Aug 5; 55(1422):62-3
The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib ( Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib ( Mekinist – GSK) for melanomas with either BRAF V600E or V600K mutations. Dabrafenib is not recommended for patients with wild-type BRAF (BRAF-negative) melanoma, and trametinib is not recommended for patients who have received prior BRAF-inhibitor therapy.
Issue 1374 · October 3, 2011
Vemurafenib (Zelboraf) for Metastatic Melanoma

The FDA has approved vemurafenib ( Zelboraf – Genentech), a kinase inhibitor, for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation, which is found in 30-60% of melanomas. An…

Med Lett Drugs Ther. 2011 Oct 3; 53(1374):77-8
The FDA has approved vemurafenib ( Zelboraf – Genentech), a kinase inhibitor, for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation, which is found in 30-60% of melanomas. An FDA-approved test can detect the mutation in DNA from melanoma tissue.
Issue 1367 · June 27, 2011
Ipilimumab (Yervoy) for Metastatic Melanoma

The FDA has approved ipilimumab ( Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.

Med Lett Drugs Ther. 2011 Jun 27; 53(1367):51-2
The FDA has approved ipilimumab ( Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.